Biopharmaceutical News and Research

RSS

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Sartorius first-quarter sales revenue increases 14.4% to 172.1 million euros

Sartorius started off fiscal 2011 with double-digit growth rates in order intake, sales revenue and profit. "We are currently seeing dynamic growth fueled by both divisions and all business regions. Compared with the year-earlier quarter, though also slightly below average, we have achieved highly encouraging rates of increase in revenue and profit," said CEO Dr. Joachim Kreuzburg.

From Sartorius 20 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

Circassia closes $98 million fundraising for lead allergy programmes

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual.

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

ARCA biopharma to sell $3 million of common stock and warrants in registered direct offering

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that it has agreed to sell approximately $3 million of its common stock and warrants to institutional investors in a registered direct offering.

18 Apr 2011

Symphony Technology Group acquires ImpactRx

ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, announced today that Symphony Technology Group (STG), has acquired a majority ownership interest in the Company. STG is a leading private equity firm with a strategic focus on data, analytics and technology-enabled services companies. Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx's existing investors, will maintain its investment in ImpactRx.

18 Apr 2011

CoDa Therapeutics raises $19.2 million in Series B financing

CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

18 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.

11 Apr 2011

PAREXEL's QbD approaches can help pharma companies maximize product quality, safety

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and the Parenteral Drug Association today announced the publication of Quality by Design: Putting Theory into Practice, written to help companies maximize product quality and safety. As increasing regulatory pressure is being placed on biopharmaceutical companies to be accountable for Quality Systems, the book serves as a definitive source on the interpretation and implementation of Quality by Design approaches.

From Parexel 11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.

8 Apr 2011

Idenix begins underwritten registered public offering of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of shares of its common stock. All of these shares are being sold by Idenix.

8 Apr 2011

Aptiv Solutions creates Adaptive Clinical Trials Innovation Center

Aptiv Solutions, a global biopharmaceutical and medical device development services company, announced today the creation of an Adaptive Clinical Trials Innovation Center.

6 Apr 2011

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Shire plc, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the Southern District of New York against Watson Pharmaceuticals, Inc. and its subsidiaries Watson Laboratories, Inc.-Florida, Watson Pharma, Inc., Andrx Corporation, and Andrx Pharmaceuticals, L.L.C. for infringement of Shire's U.S. Reissue Patent No. RE 41,148, U.S. Reissue Patent No. RE 42,096 and U.S. Patent No. 6,913,768 and also for breach of contract.

6 Apr 2011

Thermo Fisher completes Athena and Lancaster sales for $940 million

Thermo Fisher Scientific Inc., the world leader in serving science, has completed the previously announced sales of its two laboratory-testing services businesses, Athena Diagnostics and Lancaster Laboratories, in two separate transactions, resulting in total proceeds of $940 million.

From Thermo Fisher Scientific Inc. 5 Apr 2011

Biopharmaceutical News and Research

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Sartorius first-quarter sales revenue increases 14.4% to 172.1 million euros

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Cumberland acquires Vanderbilt's ifetroban rights

Circassia closes $98 million fundraising for lead allergy programmes

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

ARCA biopharma to sell $3 million of common stock and warrants in registered direct offering

Symphony Technology Group acquires ImpactRx

CoDa Therapeutics raises $19.2 million in Series B financing

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Major pharmaceutical company, Access sign deal for RNAi therapeutics

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

PAREXEL's QbD approaches can help pharma companies maximize product quality, safety

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix begins underwritten registered public offering of common stock

Aptiv Solutions creates Adaptive Clinical Trials Innovation Center

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Thermo Fisher completes Athena and Lancaster sales for $940 million

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News